Changes in markers of inflammation and their correlation with death in patients with COVID-19 in the intensive care unit.

Changes in markers of inflammation and their correlation with death in patients with COVID-19 in the intensive care unit.

Publication date: Jan 18, 2024

This study aimed to characterize the changes in serum inflammatory mediators in hospitalized patients with COVID-19 correlating with death. The study includes 58 participants: i) inpatients (n = 37): patients suffering from severe acute respiratory syndrome due to COVID-19, who were admitted at Intensive Care Unit (ICU) recovered and who died and ii) control group (n = 21): community volunteers. Inflammatory mediators evaluated interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-17 (IL-17), interferon-gamma (IFN-γ) and interferon-gamma protein levels (IFN-γ), as well as, Urea, LDH, D-dimer, TAP/INR, AST, ALT and lymphocytes. Our results suggest that high levels of inflammatory markers, such as pro-inflammatory cytokines, and laboratory parameters, such as low levels of lymphocytes and high levels of IL-6, are associated with disease severity, especially in individuals who died. Constant measurement and monitoring of these inflammatory parameters is an effective tool in clinical practice, and it can help choosing appropriate therapies during the course of the disease.

Concepts Keywords
Covid COVID-19
Death Death
Laboratory Immunity
Lymphocytes SARS-CoV-2
Pro

Semantics

Type Source Name
disease MESH inflammation
disease MESH death
disease MESH COVID-19
disease MESH severe acute respiratory syndrome
drug DRUGBANK Binetrakin
drug DRUGBANK Interleukin-10
drug DRUGBANK Urea
disease VO effective

Original Article

(Visited 1 times, 1 visits today)